Pub Date : 2025-01-24DOI: 10.1007/s10096-025-05048-1
Ruixue Wu, Xiaoyu Cui, Rui Pan, Na Li, Ying Zhang, Jianbo Shu, Yang Liu
Objectives: Neonatal sepsis is one of the causes of neonatal mortality and bacterial resistance to antibiotics is one of the challenges facing NICU. The aim of this study was to provide a basis for empirical antibiotic selection by comprehensively searching Chinese and non-Chinese databases for studies related to neonatal sepsis pathogenesis conducted in China and synthesizing all the results of the studies conducted in hospitals in China during the period under study METHODS: In this study, we conducted extensive searches of Pubmed, Web of Science, Cochrane, China Biology Medicine disc (SinoMed), China National Knowledge Infrastructure (CNKI) and Wanfang Data. We screened studies published from 2014 to 2023 that were conducted in hospitals in mainland China and involved bacterial blood cultures and susceptibility tests in neonates with neonatal sepsis and extracted the data, which were summarized using Stata 18.0 software to determine the bacterial characteristics of NS and its antimicrobial resistance in China.
Results: A total of 97 articles were finally included in the study, involving 27 provinces, municipalities and autonomous regions, and a total of 18,796 bacterial strains were isolated. Among them, Gram-positive bacteria (G+) accounted for 63.4% (95% CI 59.6%~67.3% ), and Gram-negative bacteria (G-) accounted for 36.6% (95% CI 32.7%~40.4%). The most common bacteria were, in order, Coagulase-negative Staphylococcus (43.6%, 95% CI 37.9-49.3%), Enterobacter (16.4%, 95% CI 14.8-18.1%), and Klebsiella (12.4%, 95% CI 10.8-14.0%). More than 80% of G + were resistant to penicillin, ampicillin, and benzathine, and no strains resistant to minocycline or daptomycin were found. More than 80% of G- were resistant to benzoxicillin, ampicillin, and cefotaxime, and no strains resistant to vancomycin, clindamycin, tigecycline, teicoplanin, and linezolid were identified.
Conclusion: Coagulase-negative Staphylococcus is still the main causative agent for children with neonatal sepsis in China, followed by Enterobacter and Klebsiella. In addition, Group B Streptococcus is no longer in the top three common causative agents. Resistance to penicillin antibiotics is evident among the causative organisms of neonatal sepsis in China.
{"title":"Pathogenic characterization and drug resistance of neonatal sepsis in China: a systematic review and meta-analysis.","authors":"Ruixue Wu, Xiaoyu Cui, Rui Pan, Na Li, Ying Zhang, Jianbo Shu, Yang Liu","doi":"10.1007/s10096-025-05048-1","DOIUrl":"https://doi.org/10.1007/s10096-025-05048-1","url":null,"abstract":"<p><strong>Objectives: </strong>Neonatal sepsis is one of the causes of neonatal mortality and bacterial resistance to antibiotics is one of the challenges facing NICU. The aim of this study was to provide a basis for empirical antibiotic selection by comprehensively searching Chinese and non-Chinese databases for studies related to neonatal sepsis pathogenesis conducted in China and synthesizing all the results of the studies conducted in hospitals in China during the period under study METHODS: In this study, we conducted extensive searches of Pubmed, Web of Science, Cochrane, China Biology Medicine disc (SinoMed), China National Knowledge Infrastructure (CNKI) and Wanfang Data. We screened studies published from 2014 to 2023 that were conducted in hospitals in mainland China and involved bacterial blood cultures and susceptibility tests in neonates with neonatal sepsis and extracted the data, which were summarized using Stata 18.0 software to determine the bacterial characteristics of NS and its antimicrobial resistance in China.</p><p><strong>Results: </strong>A total of 97 articles were finally included in the study, involving 27 provinces, municipalities and autonomous regions, and a total of 18,796 bacterial strains were isolated. Among them, Gram-positive bacteria (G+) accounted for 63.4% (95% CI 59.6%~67.3% ), and Gram-negative bacteria (G-) accounted for 36.6% (95% CI 32.7%~40.4%). The most common bacteria were, in order, Coagulase-negative Staphylococcus (43.6%, 95% CI 37.9-49.3%), Enterobacter (16.4%, 95% CI 14.8-18.1%), and Klebsiella (12.4%, 95% CI 10.8-14.0%). More than 80% of G + were resistant to penicillin, ampicillin, and benzathine, and no strains resistant to minocycline or daptomycin were found. More than 80% of G- were resistant to benzoxicillin, ampicillin, and cefotaxime, and no strains resistant to vancomycin, clindamycin, tigecycline, teicoplanin, and linezolid were identified.</p><p><strong>Conclusion: </strong>Coagulase-negative Staphylococcus is still the main causative agent for children with neonatal sepsis in China, followed by Enterobacter and Klebsiella. In addition, Group B Streptococcus is no longer in the top three common causative agents. Resistance to penicillin antibiotics is evident among the causative organisms of neonatal sepsis in China.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-23DOI: 10.1007/s10096-025-05043-6
Hannah K Gray, Sanchi Malhotra, Shekina Gonzalez-Ferrer, Gregory D Whitehill, Alisa C Chalmers, Shangxin Yang
We describe two cases of uncomplicated pharyngitis caused by hypervirulent Klebsiella pneumoniae (hvKp) in a family, initially in an immunocompetent adolescent, followed by possible household spread resulting in similar presentations in the patient's parent. Genomic analysis confirmed hvKp from the two cases were genetically identical and typed as K2-ST3252. Nasopharyngeal carriage and respiratory secretion/droplet may play an important yet underrecognized role in the transmission of hvKp. Enhancing routine screening for hvKp in the upper respiratory culture, followed by genotyping provides an effective pathway for early diagnosis.
{"title":"Uncomplicated pharyngitis due to family transmission of hypervirulent Klebsiella pneumoniae.","authors":"Hannah K Gray, Sanchi Malhotra, Shekina Gonzalez-Ferrer, Gregory D Whitehill, Alisa C Chalmers, Shangxin Yang","doi":"10.1007/s10096-025-05043-6","DOIUrl":"https://doi.org/10.1007/s10096-025-05043-6","url":null,"abstract":"<p><p>We describe two cases of uncomplicated pharyngitis caused by hypervirulent Klebsiella pneumoniae (hvKp) in a family, initially in an immunocompetent adolescent, followed by possible household spread resulting in similar presentations in the patient's parent. Genomic analysis confirmed hvKp from the two cases were genetically identical and typed as K2-ST3252. Nasopharyngeal carriage and respiratory secretion/droplet may play an important yet underrecognized role in the transmission of hvKp. Enhancing routine screening for hvKp in the upper respiratory culture, followed by genotyping provides an effective pathway for early diagnosis.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To evaluate diagnostic performance of four diagnostic methods for rapid determination of methicillin resistance in S. aureus positive blood cultures (BCs).
Methods: Clinical and spiked BCs were subjected to the evaluation of the following methods and protocols: a. Eazyplex® MRSA Plus loop-mediated isothermal amplification (LAMP) assay directly from BC fluid; b. MALDI-TOF MS subtyping on BC pellet extracted with Rapid Sepsityper® protocol and on 4-h short-term subculture; c. Clearview™ Culture Colony PBP2a SA immunochromatography assay on BC pellet and on 4-h short-term subculture; d. EUCAST RAST cefoxitin screen test performed directly from BC and including reading times at 4-h, 6-h and 16-20-h.
Results: Eazyplex® MRSA plus exhibited the best performance, showing 100% sensitivity, specificity, positive predictive value, and negative predictive value, followed by PBP2a SA Culture Colony Clearview assay and EUCAST RAST cefoxitin screen. MALDI-TOF MS subtyping showed the lowest diagnostic accuracy (59.8 and 65.7% directly from BC and from 4-h subculture, respectively). In detail, sensitivity and specificity ranged from 24.3% to 20.4% and from 88.9% to 98.3% for protocols performed from BC pellet and 4-h subculture, respectively.
Conclusions: The Eazyplex® MRSA Plus and the immunochromatographic Clearview™ PBP2a SA Culture Colony methods can provide reliable results within 1 h from the start of positive BC processing. MALDI TOF MS subtyping showed unacceptable specificity by performing analysis from BC pellets, while its sensitivity depends on the prevalence of PSM-positive MRSA strains. The EUCAST RAST, based on disc diffusion, showed excellent performance with a time-to-result of at least 4 h.
{"title":"Diagnostic methods and protocols for rapid determination of methicillin resistance in Staphylococcus aureus bloodstream infections: a comparative analysis.","authors":"Matteo Boattini, Luisa Guarrasi, Sara Comini, Guido Ricciardelli, Roberto Casale, Rossana Cavallo, Cristina Costa, Gabriele Bianco","doi":"10.1007/s10096-025-05039-2","DOIUrl":"https://doi.org/10.1007/s10096-025-05039-2","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate diagnostic performance of four diagnostic methods for rapid determination of methicillin resistance in S. aureus positive blood cultures (BCs).</p><p><strong>Methods: </strong>Clinical and spiked BCs were subjected to the evaluation of the following methods and protocols: a. Eazyplex<sup>®</sup> MRSA Plus loop-mediated isothermal amplification (LAMP) assay directly from BC fluid; b. MALDI-TOF MS subtyping on BC pellet extracted with Rapid Sepsityper<sup>®</sup> protocol and on 4-h short-term subculture; c. Clearview™ Culture Colony PBP2a SA immunochromatography assay on BC pellet and on 4-h short-term subculture; d. EUCAST RAST cefoxitin screen test performed directly from BC and including reading times at 4-h, 6-h and 16-20-h.</p><p><strong>Results: </strong>Eazyplex<sup>®</sup> MRSA plus exhibited the best performance, showing 100% sensitivity, specificity, positive predictive value, and negative predictive value, followed by PBP2a SA Culture Colony Clearview assay and EUCAST RAST cefoxitin screen. MALDI-TOF MS subtyping showed the lowest diagnostic accuracy (59.8 and 65.7% directly from BC and from 4-h subculture, respectively). In detail, sensitivity and specificity ranged from 24.3% to 20.4% and from 88.9% to 98.3% for protocols performed from BC pellet and 4-h subculture, respectively.</p><p><strong>Conclusions: </strong>The Eazyplex<sup>®</sup> MRSA Plus and the immunochromatographic Clearview™ PBP2a SA Culture Colony methods can provide reliable results within 1 h from the start of positive BC processing. MALDI TOF MS subtyping showed unacceptable specificity by performing analysis from BC pellets, while its sensitivity depends on the prevalence of PSM-positive MRSA strains. The EUCAST RAST, based on disc diffusion, showed excellent performance with a time-to-result of at least 4 h.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-22DOI: 10.1007/s10096-025-05044-5
Nahal Khoshdel, Melina Noursalehigarakani, Zahra Sadat Seghatoleslami, Fahimeh Hadavand, Elaheh Eghbal, Mohammad Javad Nasiri, Elena Simula, Parnian Ahmed, Leonardo Antonio Sechi
Introduction: Ceftazidime-avibactam (CAZ-AVI) has emerged as a promising treatment option for Gram-negative infections, particularly those caused by CAZ-Non-Susceptible (NS) pathogens. This systematic review and meta-analysis aim to assess the efficacy and safety of CAZ-AVI in these challenging infections.
Methods: We systematically queried EMBASE, Cochrane CENTRAL, and PubMed/Medline for studies published until September 15, 2024. Randomized Controlled Trials (RCTs) evaluating CAZ-AVI against Gram-negative infections were included. A meta-analysis was performed to calculate pooled odds ratios (OR) for both clinical and microbiological success.
Results: A total of 146 studies were identified through database searches, leading to the inclusion of 17 studies. Among the efficacy studies for Gram-negative pathogens, there was no significant difference in clinical success rates for CAZ-AVI compared to comparators (pooled OR: 0.90, p = 0.22), and a non-significant increase in microbiological success was observed (pooled OR: 1.20, p = 0.41). In contrast, for CAZ-NS pathogens, six studies reported no significant difference in clinical cure rates (pooled OR: 0.77, p = 0.24), while four studies indicated a non-significant increase in microbiological cure rates (pooled OR: 1.83, p < 0.02).
Conclusions: This study suggests that CAZ-AVI is a viable option for treating Gram-negative infections, including CAZ-NS pathogens. While it has shown promising activity against these resistant pathogens, its clinical and microbiological success rates are comparable to other antibiotics in the overall analysis. However, CAZ-AVI may offer an advantage in managing resistant infections. These findings underscore the need to consider CAZ-AVI in treatment guidelines and emphasize the importance of antibiotic stewardship programs to optimize its use and prevent resistance. Ongoing monitoring of resistance patterns and patient outcomes is essential to ensure its long-term efficacy.
头孢他啶-阿维巴坦(CAZ-AVI)已成为革兰氏阴性感染的一种有希望的治疗选择,特别是那些由caz -非敏感(NS)病原体引起的感染。本系统综述和荟萃分析旨在评估CAZ-AVI治疗这些挑战性感染的有效性和安全性。方法:系统查询EMBASE、Cochrane CENTRAL和PubMed/Medline,查询截止到2024年9月15日发表的研究。纳入评价CAZ-AVI抗革兰氏阴性感染的随机对照试验(RCTs)。进行荟萃分析以计算临床和微生物学成功的合并优势比(OR)。结果:通过数据库检索共发现146项研究,纳入17项研究。在革兰氏阴性病原体的疗效研究中,CAZ-AVI的临床成功率与比较物相比无显著差异(合并OR: 0.90, p = 0.22),微生物成功率无显著增加(合并OR: 1.20, p = 0.41)。相比之下,对于CAZ-NS病原体,6项研究报告临床治愈率无显著差异(合并OR: 0.77, p = 0.24),而4项研究报告微生物治愈率无显著增加(合并OR: 1.83, p)。结论:本研究表明CAZ-AVI是治疗革兰氏阴性感染的可行选择,包括CAZ-NS病原体。虽然它对这些耐药病原体显示出有希望的活性,但在总体分析中,其临床和微生物学成功率与其他抗生素相当。然而,CAZ-AVI可能在管理耐药感染方面具有优势。这些发现强调了在治疗指南中考虑CAZ-AVI的必要性,并强调了抗生素管理计划对优化其使用和预防耐药性的重要性。持续监测耐药模式和患者预后对于确保其长期疗效至关重要。
{"title":"Efficacy of Ceftazidime-avibactam in treating Gram-negative infections: a systematic review and meta-analysis.","authors":"Nahal Khoshdel, Melina Noursalehigarakani, Zahra Sadat Seghatoleslami, Fahimeh Hadavand, Elaheh Eghbal, Mohammad Javad Nasiri, Elena Simula, Parnian Ahmed, Leonardo Antonio Sechi","doi":"10.1007/s10096-025-05044-5","DOIUrl":"https://doi.org/10.1007/s10096-025-05044-5","url":null,"abstract":"<p><strong>Introduction: </strong>Ceftazidime-avibactam (CAZ-AVI) has emerged as a promising treatment option for Gram-negative infections, particularly those caused by CAZ-Non-Susceptible (NS) pathogens. This systematic review and meta-analysis aim to assess the efficacy and safety of CAZ-AVI in these challenging infections.</p><p><strong>Methods: </strong>We systematically queried EMBASE, Cochrane CENTRAL, and PubMed/Medline for studies published until September 15, 2024. Randomized Controlled Trials (RCTs) evaluating CAZ-AVI against Gram-negative infections were included. A meta-analysis was performed to calculate pooled odds ratios (OR) for both clinical and microbiological success.</p><p><strong>Results: </strong>A total of 146 studies were identified through database searches, leading to the inclusion of 17 studies. Among the efficacy studies for Gram-negative pathogens, there was no significant difference in clinical success rates for CAZ-AVI compared to comparators (pooled OR: 0.90, p = 0.22), and a non-significant increase in microbiological success was observed (pooled OR: 1.20, p = 0.41). In contrast, for CAZ-NS pathogens, six studies reported no significant difference in clinical cure rates (pooled OR: 0.77, p = 0.24), while four studies indicated a non-significant increase in microbiological cure rates (pooled OR: 1.83, p < 0.02).</p><p><strong>Conclusions: </strong>This study suggests that CAZ-AVI is a viable option for treating Gram-negative infections, including CAZ-NS pathogens. While it has shown promising activity against these resistant pathogens, its clinical and microbiological success rates are comparable to other antibiotics in the overall analysis. However, CAZ-AVI may offer an advantage in managing resistant infections. These findings underscore the need to consider CAZ-AVI in treatment guidelines and emphasize the importance of antibiotic stewardship programs to optimize its use and prevent resistance. Ongoing monitoring of resistance patterns and patient outcomes is essential to ensure its long-term efficacy.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-21DOI: 10.1007/s10096-025-05041-8
S Douiyeb, K C E Sigaloff, E G Ulas, M G J Duffels, O Drexhage, T Germans, J F P Wagenaar, D T P Buis, T W van der Vaart, C H van Werkhoven, J M Prins, V A W M Umans
Purpose: Infective endocarditis (IE) can be complicated by vertebral osteomyelitis (VO). This study investigates risk factors associated with VO in patients with infective endocarditis, and 6-month mortality and relapse rates in patients with IE and concomitant VO.
Methods: We performed a observational study in two hospitals between September 2016 and October 2022. Patients with possible or definite IE according European Society of Cardiology (2015) modified criteria were retrieved from the local endocarditis team registries. The VO diagnosis was based on radiological signs, irrespective of clinical symptoms. Multivariable logistic regression analysis was performed to identify risk factors for vertebral osteomyelitis.
Results: We included 633 consecutive patients with IE. A total of 229 (36.2%) patients had prosthetic valves and 127 (20.1%) had cardiac implantable electronic devices. The most frequent causative micro-organism was Streptococcus species (217, 34.3%), followed by Staphylococcus aureus (167, 26.4%). VO was diagnosed in 73 patients (11.5%, 95% CI 9.0%-14.0%). Enterococcus spp.(OR 2.48, 95% CI 1.31-4.52) and age (OR 1.04 per year, 95% CI 1.02-1.06) were independently associated with concomitant VO. The 6-month mortality risk did not differ between patients with (16/73, 21.9%) or without (110/560, 19.6%) VO (HR 1.13, 95% CI 0.67-1.91). Relapse rate was higher in patients with VO but the difference was not statistically significant (16.1 vs. 7.5%, OR 3.62, 95% CI 0.94-13.34).
Conclusions: Twelve percent of patients with IE also had VO. Among older patients and patients with IE caused by enterococci, there should be a higher index of suspicion for vertebral infection.
目的:感染性心内膜炎(IE)可并发椎体骨髓炎(VO)。本研究调查了感染性心内膜炎患者发生VO的相关危险因素,以及IE合并VO患者的6个月死亡率和复发率。方法:我们于2016年9月至2022年10月在两家医院进行观察性研究。根据欧洲心脏病学会(2015)修改的标准,从当地心内膜炎小组登记处检索可能或明确的IE患者。VO诊断基于影像学征象,与临床症状无关。采用多变量logistic回归分析确定椎体骨髓炎的危险因素。结果:我们纳入了633例连续的IE患者。229例(36.2%)患者使用人工瓣膜,127例(20.1%)患者使用心脏植入式电子装置。最常见的病原菌是链球菌(217种,34.3%),其次是金黄色葡萄球菌(167种,26.4%)。73例患者被诊断为VO (11.5%, 95% CI 9.0%-14.0%)。肠球菌(OR 2.48, 95% CI 1.31-4.52)和年龄(OR 1.04 /年,95% CI 1.02-1.06)与伴随的VO独立相关。VO患者(16/73,21.9%)和VO患者(110/560,19.6%)6个月死亡风险无差异(HR 1.13, 95% CI 0.67-1.91)。VO患者复发率较高,但差异无统计学意义(16.1 vs. 7.5%, OR 3.62, 95% CI 0.94-13.34)。结论:12%的IE患者也有VO。在老年患者和肠球菌引起的IE患者中,椎体感染的怀疑指数应该更高。
{"title":"Vertebral osteomyelitis in patients with infective endocarditis: prevalence, risk factors and mortality.","authors":"S Douiyeb, K C E Sigaloff, E G Ulas, M G J Duffels, O Drexhage, T Germans, J F P Wagenaar, D T P Buis, T W van der Vaart, C H van Werkhoven, J M Prins, V A W M Umans","doi":"10.1007/s10096-025-05041-8","DOIUrl":"https://doi.org/10.1007/s10096-025-05041-8","url":null,"abstract":"<p><strong>Purpose: </strong>Infective endocarditis (IE) can be complicated by vertebral osteomyelitis (VO). This study investigates risk factors associated with VO in patients with infective endocarditis, and 6-month mortality and relapse rates in patients with IE and concomitant VO.</p><p><strong>Methods: </strong>We performed a observational study in two hospitals between September 2016 and October 2022. Patients with possible or definite IE according European Society of Cardiology (2015) modified criteria were retrieved from the local endocarditis team registries. The VO diagnosis was based on radiological signs, irrespective of clinical symptoms. Multivariable logistic regression analysis was performed to identify risk factors for vertebral osteomyelitis.</p><p><strong>Results: </strong>We included 633 consecutive patients with IE. A total of 229 (36.2%) patients had prosthetic valves and 127 (20.1%) had cardiac implantable electronic devices. The most frequent causative micro-organism was Streptococcus species (217, 34.3%), followed by Staphylococcus aureus (167, 26.4%). VO was diagnosed in 73 patients (11.5%, 95% CI 9.0%-14.0%). Enterococcus spp.(OR 2.48, 95% CI 1.31-4.52) and age (OR 1.04 per year, 95% CI 1.02-1.06) were independently associated with concomitant VO. The 6-month mortality risk did not differ between patients with (16/73, 21.9%) or without (110/560, 19.6%) VO (HR 1.13, 95% CI 0.67-1.91). Relapse rate was higher in patients with VO but the difference was not statistically significant (16.1 vs. 7.5%, OR 3.62, 95% CI 0.94-13.34).</p><p><strong>Conclusions: </strong>Twelve percent of patients with IE also had VO. Among older patients and patients with IE caused by enterococci, there should be a higher index of suspicion for vertebral infection.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-21DOI: 10.1007/s10096-024-05034-z
Salud Rodríguez-Pallares, María Alejandra Mateo-Vargas, Manuel Antonio Rodríguez-Iglesias, Jorge Arca-Suárez, Fátima Galán-Sánchez
Purpose: To prospectively monitor the evolution of the resistome of OXA-48-producing Klebsiella species in a patient with long-term colonization, with a particular focus into the plasmid dynamics and the evolution of ceftazidime/avibactam resistance.
Methods: All OXA-48-producing Klebsiella spp. isolates from a single patient admitted to a hospital during seven months were prospectively collected. MICs were determined through reference broth microdilution. Multilocus sequence types, SNPs analysis, resistance mechanisms, genetic context of β-lactamases and plasmid dynamics were determined by WGS and bioinformatic analysis. The impact of β-lactamase variant obtained after ceftazidime/avibactam exposure was determined via cloning experiments.
Results: Four isolates, two before (one OXA-48-producing K. pneumoniae and one CTX-M-15-like-producing K. pneumoniae) and two after treatment with ceftazidime/avibactam (one OXA-48- and CTX-M-15-like-producing K. pneumoniae and one OXA-48- and CTX-M-15-like-producing K. aerogenes) were collected. The plasmid dynamics analysis demonstrated that the IncL and IncFIIK plasmids, in which blaOXA-48 and blaCTX-M-15-like genes were located, respectively, exhibited a high degree of conservation indicating a potential for both intra- and interspecies transmission. The K. pneumoniae isolate obtained after treatment, which differed from the previous isolate by just six SNPs, exhibited resistance to ceftazidime/avibactam through P167S substitution in CTX-M-15, which is now designated CTX-M-273. Cloning experiments demonstrated enhanced resistance to ceftazidime/avibactam.
Conclusion: The transfer of plasmid-borne β-lactamase resistance genes between intra- and interspecies bacterial populations enables the rapid diversification of the bacterial genome. The emergence of ceftazidime/avibactam resistance through the modification of CTX-M-enzymes represents a mechanism by which OXA-48-producing Enterobacterales may evolve toward ceftazidime/avibactam resistance in vivo.
目的:前瞻性监测长期定殖患者产生oxa -48克雷伯菌的抗性组进化,特别关注质粒动力学和头孢他啶/阿维巴坦耐药性的进化。方法:前瞻性收集1例住院患者7个月内所有产oxa -48克雷伯氏菌分离株。通过参考肉汤微量稀释测定mic。通过WGS和生物信息学分析确定了β-内酰胺酶的多位点序列类型、snp分析、抗性机制、遗传背景和质粒动力学。通过克隆实验确定头孢他啶/阿维巴坦暴露后β-内酰胺酶变异的影响。结果:共收集到4株分离株,其中2株为头孢他嗪/阿维巴坦治疗前分离株(1株产OXA-48肺炎克雷伯菌和1株产ctx - m -15样肺炎克雷伯菌),2株为头孢他嗪/阿维巴坦治疗后分离株(1株产OXA-48和ctx - m -15样肺炎克雷伯菌和1株产OXA-48和ctx - m -15样肺克雷伯菌)。质粒动力学分析表明,分别含有blaOXA-48和blactx - m -15样基因的IncL和IncFIIK质粒具有高度保守性,具有种内和种间传播的潜力。治疗后获得的肺炎克雷伯菌分离株与之前的分离株仅差异6个snp,通过在CTX-M-15(现在称为CTX-M-273)中P167S取代,表现出对头孢他啶/阿维巴坦的耐药性。克隆实验显示对头孢他啶/阿维巴坦的抗性增强。结论:质粒携带的β-内酰胺酶耐药基因在细菌种群内和种间的转移使细菌基因组快速多样化。通过ctx - m酶修饰产生头孢他啶/阿维巴坦耐药,代表了产生oxa -48的肠杆菌在体内向头孢他啶/阿维巴坦耐药进化的一种机制。
{"title":"Evolution of ceftazidime/avibactam resistance and plasmid dynamics in OXA-48-producing Klebsiella spp. during long-term patient colonization.","authors":"Salud Rodríguez-Pallares, María Alejandra Mateo-Vargas, Manuel Antonio Rodríguez-Iglesias, Jorge Arca-Suárez, Fátima Galán-Sánchez","doi":"10.1007/s10096-024-05034-z","DOIUrl":"https://doi.org/10.1007/s10096-024-05034-z","url":null,"abstract":"<p><strong>Purpose: </strong>To prospectively monitor the evolution of the resistome of OXA-48-producing Klebsiella species in a patient with long-term colonization, with a particular focus into the plasmid dynamics and the evolution of ceftazidime/avibactam resistance.</p><p><strong>Methods: </strong>All OXA-48-producing Klebsiella spp. isolates from a single patient admitted to a hospital during seven months were prospectively collected. MICs were determined through reference broth microdilution. Multilocus sequence types, SNPs analysis, resistance mechanisms, genetic context of β-lactamases and plasmid dynamics were determined by WGS and bioinformatic analysis. The impact of β-lactamase variant obtained after ceftazidime/avibactam exposure was determined via cloning experiments.</p><p><strong>Results: </strong>Four isolates, two before (one OXA-48-producing K. pneumoniae and one CTX-M-15-like-producing K. pneumoniae) and two after treatment with ceftazidime/avibactam (one OXA-48- and CTX-M-15-like-producing K. pneumoniae and one OXA-48- and CTX-M-15-like-producing K. aerogenes) were collected. The plasmid dynamics analysis demonstrated that the IncL and IncFIIK plasmids, in which bla<sub>OXA-48</sub> and bla<sub>CTX-M-15-like</sub> genes were located, respectively, exhibited a high degree of conservation indicating a potential for both intra- and interspecies transmission. The K. pneumoniae isolate obtained after treatment, which differed from the previous isolate by just six SNPs, exhibited resistance to ceftazidime/avibactam through P167S substitution in CTX-M-15, which is now designated CTX-M-273. Cloning experiments demonstrated enhanced resistance to ceftazidime/avibactam.</p><p><strong>Conclusion: </strong>The transfer of plasmid-borne β-lactamase resistance genes between intra- and interspecies bacterial populations enables the rapid diversification of the bacterial genome. The emergence of ceftazidime/avibactam resistance through the modification of CTX-M-enzymes represents a mechanism by which OXA-48-producing Enterobacterales may evolve toward ceftazidime/avibactam resistance in vivo.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: The aim is to encourage the creation of innovative prevention and treatment measures and to help readers in selecting the most effective ones.
Background: Acne vulgaris is the most prevalent skin condition of adolescents, affecting approximately 9% of the global population. Patients become more prone to mental and psychological problems because of it. Several strategies have been established to effectively improve acne vulgaris. However, the complexity of its pathogenesis and the limitations of the existing strategies to control it in terms of bacterial resistance, patient compliance, and safety have made the development of new control strategies a hot topic in skin health research.
Results: This review systematically summarizes the pathogenesis and prevention strategies of acne vulgaris according to the most recent studies. The limitations of the current research on acne vulgaris and future research directions are presented based on the analysis of the strengths and weaknesses of the existing prevention and treatment strategies.
{"title":"Acne vulgaris: advances in pathogenesis and prevention strategies.","authors":"Weiping Xu, Jiahui Xu, Dandan Huang, Chen Wang, Jiajia Song, Xiaoyong Chen, Huayi Suo","doi":"10.1007/s10096-024-04984-8","DOIUrl":"https://doi.org/10.1007/s10096-024-04984-8","url":null,"abstract":"<p><strong>Purpose: </strong>The aim is to encourage the creation of innovative prevention and treatment measures and to help readers in selecting the most effective ones.</p><p><strong>Background: </strong>Acne vulgaris is the most prevalent skin condition of adolescents, affecting approximately 9% of the global population. Patients become more prone to mental and psychological problems because of it. Several strategies have been established to effectively improve acne vulgaris. However, the complexity of its pathogenesis and the limitations of the existing strategies to control it in terms of bacterial resistance, patient compliance, and safety have made the development of new control strategies a hot topic in skin health research.</p><p><strong>Results: </strong>This review systematically summarizes the pathogenesis and prevention strategies of acne vulgaris according to the most recent studies. The limitations of the current research on acne vulgaris and future research directions are presented based on the analysis of the strengths and weaknesses of the existing prevention and treatment strategies.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-14DOI: 10.1007/s10096-025-05037-4
Gabriel Victor Castanheira, Valdir Sabbaga Amato, Felipe Francisco Tuon, Letícia Ramos Dantas, Silvio Fernando Guimarães de Carvalho, Thallyta Maria Vieira, Ana Paula Venuto Moura, Jackeline Maria de Sousa Lima Lopes, Gustavo Henrique Johanson, Christini Takemi Emori, Regina Maia de Souza
This study aimed to standardize qPCR techniques using these molecular markers kDNA and 18S rDNA across three sample types: peripheral blood, guanidine-treated blood, and tissue. The secondary objective is to evaluate the performance of 18S rDNA target in samples from 46 patients with confirmed tegumentary leishmaniasis. After obtaining the standard curve from reference strains with Leishmania, qPCR curves were standardizations and the Cts results of the patient samples were described using abstract measures. Specific specification equations (EEG) with normal distribution and identity link function were constructed to compare each type of clinical sample. To identify the differences among samples and techniques, multiple comparisons with Bonferroni post-test was performed. The kDNA and 18S rDNA demonstrated high sensitivity, detecting as few as 10⁻1 parasites/mL. However, 18S rDNA showed limited species discrimination. qPCR performance was evaluated using blood and tissue samples, showing a sensitivity of 54.2% in blood, 12.5% in guanidine-treated blood, and 86.4% in tissue. qPCR agreement with the 18S rDNA target with the three types of samples, positive and negative, in relation to screening were 56.2% in blood, 31.8% in guanidine- blood and tissue 78.6%. As for true positives (PPV), tissue samples presented a probability percentage of individuals being sick of 86.4%, while in blood it was 81.3%. The results underscore the importance of molecular diagnostics in blood samples, improving the accuracy and monitoring of tegumentary leishmaniasis.
{"title":"High detection rate of parasitic load by qPCR targeting 18S rDNA in blood of patients with active leishmaniasis lesions.","authors":"Gabriel Victor Castanheira, Valdir Sabbaga Amato, Felipe Francisco Tuon, Letícia Ramos Dantas, Silvio Fernando Guimarães de Carvalho, Thallyta Maria Vieira, Ana Paula Venuto Moura, Jackeline Maria de Sousa Lima Lopes, Gustavo Henrique Johanson, Christini Takemi Emori, Regina Maia de Souza","doi":"10.1007/s10096-025-05037-4","DOIUrl":"https://doi.org/10.1007/s10096-025-05037-4","url":null,"abstract":"<p><p>This study aimed to standardize qPCR techniques using these molecular markers kDNA and 18S rDNA across three sample types: peripheral blood, guanidine-treated blood, and tissue. The secondary objective is to evaluate the performance of 18S rDNA target in samples from 46 patients with confirmed tegumentary leishmaniasis. After obtaining the standard curve from reference strains with Leishmania, qPCR curves were standardizations and the Cts results of the patient samples were described using abstract measures. Specific specification equations (EEG) with normal distribution and identity link function were constructed to compare each type of clinical sample. To identify the differences among samples and techniques, multiple comparisons with Bonferroni post-test was performed. The kDNA and 18S rDNA demonstrated high sensitivity, detecting as few as 10⁻<sup>1</sup> parasites/mL. However, 18S rDNA showed limited species discrimination. qPCR performance was evaluated using blood and tissue samples, showing a sensitivity of 54.2% in blood, 12.5% in guanidine-treated blood, and 86.4% in tissue. qPCR agreement with the 18S rDNA target with the three types of samples, positive and negative, in relation to screening were 56.2% in blood, 31.8% in guanidine- blood and tissue 78.6%. As for true positives (PPV), tissue samples presented a probability percentage of individuals being sick of 86.4%, while in blood it was 81.3%. The results underscore the importance of molecular diagnostics in blood samples, improving the accuracy and monitoring of tegumentary leishmaniasis.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142978137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-07DOI: 10.1007/s10096-024-05030-3
Moritz Fritzenwanker, Marcel O Grabitz, Vera Negwer, Oliver Schwengers, Borros Arneth, Trinad Chakraborty, Can Imirzalioglu, Florian Wagenlehner
Purpose: We designed and tested a point of care test panel to detect E.coli and antibiotic susceptibility in urine samples from patients at the point of care in the urological department. The aim of this approach is to facilitate choosing an appropriate antibiotic for urinary tract infections (UTI) at first presentation in the context of increasing antibiotic resistance in uropathogens worldwide.
Methods: We analyzed 162 E.coli isolates from samples from a university urological department to determine phenotypic and genotypic resistance data. With this data we created customized LAMP (loop-mediated isothermal amplification) panels for a commercial machine with which to detect and possibly quantify E.coli and six antibiotic resistance determinants. In a second step we tested these panel(s) for diagnostic accuracy on 1596 urine samples and compared with routine microbiological culture.
Results: E.coli was detected with 95.4% sensitivity and 96.1% specificity. Dynamics of the LAMP amplification could be used to gauge bacterial loads in the samples. Antibiotic sensitivity was detected with good negative (sensitive) predictive values: ampicillin 92.8%, ampicillin/sulbactam 96.4%, cefuroxime 92.8%, cefotaxime 97.8%, trimethoprim/sulfamethoxazole 96.5%, ciprofloxacin 96.8%.
Conclusion: The LAMP panel provided E.coli detection and sensitivity information within one hour and thus could principally guide initial antibiotic therapy upon patients presenting with UTI. The panel helps to select initial adequate antibiotic therapy as well as providing diagnostic stewardship. Follow up investigations will expand the test system to other uropathogens.
{"title":"Genome-based development and clinical evaluation of a customized LAMP panel to rapidly detect, quantify, and determine antibiotic sensitivity of Escherichia coli in native urine samples from urological patients.","authors":"Moritz Fritzenwanker, Marcel O Grabitz, Vera Negwer, Oliver Schwengers, Borros Arneth, Trinad Chakraborty, Can Imirzalioglu, Florian Wagenlehner","doi":"10.1007/s10096-024-05030-3","DOIUrl":"https://doi.org/10.1007/s10096-024-05030-3","url":null,"abstract":"<p><strong>Purpose: </strong>We designed and tested a point of care test panel to detect E.coli and antibiotic susceptibility in urine samples from patients at the point of care in the urological department. The aim of this approach is to facilitate choosing an appropriate antibiotic for urinary tract infections (UTI) at first presentation in the context of increasing antibiotic resistance in uropathogens worldwide.</p><p><strong>Methods: </strong>We analyzed 162 E.coli isolates from samples from a university urological department to determine phenotypic and genotypic resistance data. With this data we created customized LAMP (loop-mediated isothermal amplification) panels for a commercial machine with which to detect and possibly quantify E.coli and six antibiotic resistance determinants. In a second step we tested these panel(s) for diagnostic accuracy on 1596 urine samples and compared with routine microbiological culture.</p><p><strong>Results: </strong>E.coli was detected with 95.4% sensitivity and 96.1% specificity. Dynamics of the LAMP amplification could be used to gauge bacterial loads in the samples. Antibiotic sensitivity was detected with good negative (sensitive) predictive values: ampicillin 92.8%, ampicillin/sulbactam 96.4%, cefuroxime 92.8%, cefotaxime 97.8%, trimethoprim/sulfamethoxazole 96.5%, ciprofloxacin 96.8%.</p><p><strong>Conclusion: </strong>The LAMP panel provided E.coli detection and sensitivity information within one hour and thus could principally guide initial antibiotic therapy upon patients presenting with UTI. The panel helps to select initial adequate antibiotic therapy as well as providing diagnostic stewardship. Follow up investigations will expand the test system to other uropathogens.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-06DOI: 10.1007/s10096-024-05027-y
Flavia Pennisi, Antonio Pinto, Giovanni Emanuele Ricciardi, Carlo Signorelli, Vincenza Gianfredi
The increasing threat of antimicrobial resistance has prompted a need for more effective antimicrobial stewardship programs (AMS). Artificial intelligence (AI) and machine learning (ML) tools have emerged as potential solutions to enhance decision-making and improve patient outcomes in AMS. This systematic review and meta-analysis aims to evaluate the impact of AI in AMS and to assess its predictive performance and diagnostic accuracy. We conducted a comprehensive literature search across PubMed/MEDLINE, Scopus, EMBASE, and Web of Science to identify studies published up to July 2024. Studies included were observational, cohort, or retrospective, focusing on the application of AI/ML in AMS. The outcomes assessed were the area under the curve (AUC), accuracy, sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV). We calculated the mean pooled effect size (ES) and its 95% confidence interval (CI) using a random-effects model. The risk of bias was assessed using the QUADAS-AI tool, and the protocol was registered in PROSPERO. Out of 3,458 retrieved articles, 80 studies met the inclusion criteria. Our meta-analysis demonstrated that ML models exhibited strong predictive performance and diagnostic accuracy, with the following results: AUC [ES: 72.28 (70.42-74.14)], accuracy [ES: 74.97 (73.35-76.58)], sensitivity [ES: 76.89; (71.90-81.89)], specificity [ES: 73.77; (67.87-79.67)], NPV [ES:79.92 (76.54-83.31)], and PPV [ES: 69.41 (60.19-78.63)] across various AMS settings. AI and ML tools offer promising enhancements due to their strong predictive performance. The integration of AI into AMS could lead to more precise antimicrobial prescribing, reduced antimicrobial resistance, and better resource utilization.
{"title":"Artificial intelligence in antimicrobial stewardship: a systematic review and meta-analysis of predictive performance and diagnostic accuracy.","authors":"Flavia Pennisi, Antonio Pinto, Giovanni Emanuele Ricciardi, Carlo Signorelli, Vincenza Gianfredi","doi":"10.1007/s10096-024-05027-y","DOIUrl":"https://doi.org/10.1007/s10096-024-05027-y","url":null,"abstract":"<p><p>The increasing threat of antimicrobial resistance has prompted a need for more effective antimicrobial stewardship programs (AMS). Artificial intelligence (AI) and machine learning (ML) tools have emerged as potential solutions to enhance decision-making and improve patient outcomes in AMS. This systematic review and meta-analysis aims to evaluate the impact of AI in AMS and to assess its predictive performance and diagnostic accuracy. We conducted a comprehensive literature search across PubMed/MEDLINE, Scopus, EMBASE, and Web of Science to identify studies published up to July 2024. Studies included were observational, cohort, or retrospective, focusing on the application of AI/ML in AMS. The outcomes assessed were the area under the curve (AUC), accuracy, sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV). We calculated the mean pooled effect size (ES) and its 95% confidence interval (CI) using a random-effects model. The risk of bias was assessed using the QUADAS-AI tool, and the protocol was registered in PROSPERO. Out of 3,458 retrieved articles, 80 studies met the inclusion criteria. Our meta-analysis demonstrated that ML models exhibited strong predictive performance and diagnostic accuracy, with the following results: AUC [ES: 72.28 (70.42-74.14)], accuracy [ES: 74.97 (73.35-76.58)], sensitivity [ES: 76.89; (71.90-81.89)], specificity [ES: 73.77; (67.87-79.67)], NPV [ES:79.92 (76.54-83.31)], and PPV [ES: 69.41 (60.19-78.63)] across various AMS settings. AI and ML tools offer promising enhancements due to their strong predictive performance. The integration of AI into AMS could lead to more precise antimicrobial prescribing, reduced antimicrobial resistance, and better resource utilization.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}